bioRxiv ScienceSearch

bioRxiv · 10.1101/2020.12.03.411124

In vivo Evaluation and in silico Prediction of the Toxicity of Drepanoalpha Hard capsules

Abstract

GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=95 SRC="FIGDIR/small/411124v3_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@12dbf1aorg.highwire.dtl.DTLVardef@5d6e9forg.highwire.dtl.DTLVardef@9ba26org.highwire.dtl.DTLVardef@9c2017_HPS_FORMAT_FIGEXP M_FIG C_FIG ABSTRACTO_ST_ABSEthnopharmacological relevanceC_ST_ABSDrepanoalpha(R) hard capsules, a dry ethanolic extract (drug-extract ratio, 100/11) of a mixture of Justicia secunda Vahl and Moringa oleifera Lam dried leaves (1: 1, w/w) are used for the management of sickle cell disease in the Democratic Republic of Congo. Aim of the studyThis phytomedicine safety was investigated by acute and sub-acute administration in Guinea pigs. Materials and methodsHealthy, male and nulliparous and non-pregnant female Guinea pigs were obtained from "Laboratory of Animal Experimentation and Toxicology" of the Department of Biology, Faculty of Sciences, University of Kinshasa. The animals were randomly selected, marked and divided into 2 groups of 5 animals each (3 males and 2 females) and 4 groups of 3 animals each for acute and sub-acute toxicity studies, respectively. The contents of hard capsules were dissolved in normal saline solution (NaCl 9 {per thousand}). Animals received by gavage a single dose of 5000 mg/ kg of body weight (B.W.) of Drepanoalpha(R) hard capsules (acute toxicity) and 125 mg/ kg, 250 mg/ kg and 500 mg/ kg of B.W. twice daily for 28 days (sub-acute toxicity). Normal saline solution was used as control. Hematological, biochemical and histopathological analyses were performed and the behavior of the animals was observed after treatment. ResultsThe median lethal dose (LD50) is higher than 5000 mg/ kg of B.W., and the relative weights of vital organs (kidneys, liver and heart) collected from Guinea pigs at the end of treatment on D14 (acute toxicity) and D28 (sub-acute toxicity) has not undergone significant changes (p > 0.05). The results of haematological (red and white blood cells counts, haemoglobin, haematocrit) and biochemical (ALT, AST, albumin, total protein) tests did not show significant differences between control and test groups (=0.05 for acute toxicity), while the histopathological study revealed no damage to the various organs excised. ConclusionThe results indicate the safety of Drepanoalpha(R) hard capsules, confirming previous studies, in rats and Guinea pigs, based on aqueous decoction of its raw herbs mixtures and the corresponding lyophilizate.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Gbolo Zoawe, B., Ngbolua Koto-te-Nyiwa, J.-P., Tshibangu Sha-Tshibey, D., Memvanga Bondo, P., Tshilanda Dinangayi, D., Matondo, A., Kilembe Thambwe, J., Lebwaze Masamba, B., Nachtergael, A., Mpiana Tshimankinda, P., Duez, P.. 2020-12-04. In vivo Evaluation and in silico Prediction of the Toxicity of Drepanoalpha Hard capsules. https://doi.org/10.1101/2020.12.03.411124

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology

AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In Vivo

Infections from the SARS-CoV-2 virus have killed over 4.6 million people since it began spreading through human populations in late 2019. In order to develop a therapeutic or prophylactic antibody to help mitigate the effects of the pandemic, a human monoclonal antibody (mAb) that binds to the SARS-CoV-2 spike protein was isolated from a convalescent patient following recovery from COVID-19 disease. This mAb, designated AUG-3387, demonstrates a high affinity for the spike protein of the original viral strains and all variants tested to date. In vitro pseudovirus neutralization and SARS-CoV-2 neutralization activity has been demonstrated in vitro. In addition, a dry powder formulation has been prepared using a Thin-Film Freezing (TFF) process that exhibited a fine particle fraction (FPF) of 50.95 {+/-} 7.69% and a mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of 3.74 {+/-} 0.73 {micro}m and 2.73 {+/-} 0.20, respectively. The dry powder is suitable for delivery directly to the lungs of infected patients using a dry powder inhaler device. Importantly, AUG-3387, administered as a liquid by intraperitoneal injection or the dry powder formulation delivered intratracheally into Syrian hamsters 24 hours after intranasal SARS-CoV-2 infection, demonstrated a dose-dependent reduction in the lung viral load of the virus. These data suggest that AUG-3387 formulated as a dry powder demonstrates potential to treat COVID-19.

pharmacology and toxicology